PAVmed to Present at Rodman & Renshaw Global Investment Conference

Life Science Investing News

PAVmed Inc., a highly differentiated, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016.

NEW YORK–(BUSINESS WIRE)–PAVmed Inc. (NADAQ:PAVM), a highly differentiated, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the
Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016, at 5:05 pm ET taking place at the Lotte New York Palace Hotel in New York City. Dr. Aklog will provide a corporate overview, discuss the company’s innovative business model and review PAVmed’s lead products.
To access the live webcast of the presentation, please click here. A replay will be available following the presentation.

About PAVmed

PAVmed Inc. is a highly differentiated, multi-product medical device company employing a unique business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding multi-product pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs, have attractive regulatory pathways and market opportunities and encompass a broad spectrum of clinical areas including carpal tunnel syndrome (CarpX™), medical infusions (NextFlo™ and NextCath™), interventional radiology (PortIO™ and NextCath), tissue ablation and cardiovascular intervention (Caldus™). The Company intends to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please visit www.pavm.com.
Don’t forget to follow us @INN_LifeScience for real-time news updates.

The Conversation (0)
×